Pfizer, the New York City-based big pharmaceutical company, inked a multiyear partnership with Tel Aviv, Israel-based CytoReason, a technology company developing computational disease models.
Per the agreement, Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform, and will fund supplementary project support. According to the release, the deal total amount is worth up to $110 million over the next five years.
Since 2019, Pfizer has used CytoReason’s machine learning biological models in its research to enhance the understanding of the immune system and provide research into 20 diseases. This funding will accelerate the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.
“CytoReason’s biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective,” Mikael Dolsten, chief scientific officer of Pfizer, said in a prepared statement.
It’s the latest deal between a big pharma and an AI company. Along with Pfizer, GlaxoSmithKline, Merck, Eli Lilly, Novartis, Bristol Myers Squibb, AmerisourceBergen and other big pharma companies have all made digital health plays in the last few months. Last week, Novo Nordisk, a big pharmaceutical company, entered into a strategic agreement with Microsoft to enhance Novo Nordisk’s drug discovery, development and data science services.